课题基金 / 基金详情

SAFETY, PHARMACOKINETIC/PHARMACODYNAMIC EFFECT OF PEG HIRUDIN ON ANTICOAGULATION

SAFETY, PHARMACOKINETIC/PHARMACODYNAMIC EFFECT OF PEG HIRUDIN ON ANTICOAGULATION
聚乙二醇水蛭素抗凝的安全性、药代动力学/药效学作用
批准号:
6115137
负责人:
JAMES H CHESEBRO
金额:
$6.88万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

JAMES H CHESEBRO的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objective of this study is to determine the optimal dosage of PEG- Hirudin in patients with unstable angina or non Q-wave myocardial infarction and also to compare its efficacy to that of standard drug therapy with heparin. The decision to give heparin, or to give PEG- Hirudin, will be made randomly by a computer after patient has given consent to participate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLOPIDOGREL DOSING IN HUMAN ARTERIAL THROMBUS FORMATION
CLOPIDOGREL DOSING IN HUMAN ARTERIAL THROMBUS FORMATION
ANTITHROMBOTIC EFFECT OF ESCALATING DOSES OF PEG HIRUDIN IN HUMANS
LIPID LOWERING WITH SIMVASTATINE AFTER ACURE CORONARY SYNDROMES